Feng Zhang
Co-Founder & Scientific Advisory Board MemberDr. Feng Zhang, Ph.D. serves as Member of Scientific Advisory Board of Octant, Inc. He serves as Scientific Founder at Aera Therapeutics and serves as its Board Observer since 2025. He is Co-Founder of Pairwise Plants, LLC. He serves as Member of Scientific Advisory Board since 2021 at BioInnovation Institute. He is a Co-founder and Scientific Advisory Board Chair at Arbor Biotechnologies, Inc. He is Co-Founder of Beam Therapeutics Inc. Dr. Zhang served as Co-Founder and Chair of Advisory Board at Sherlock Biosciences, Inc. until 2022. He had been Member of Scientific Advisory Board at PureTech Health plc since July 8, 2016. Dr. Zhang co-founded Editas Medicine Inc. in 2013. Dr. Zhang is an accomplished bioengineer focused on developing tools to better understand nervous system function and disease. He serves as W.M. Keck Career Development Professor with joint appointment in Biological Engineering and also Brain and Cognitive Sciences departments at the Massachusetts Institute of Technology (MIT). He served as a Joint Assistant Professor in the Departments of Brain and Cognitive Sciences and Biological Engineering at Massachusetts Institute of Technology. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is working to extend this molecular engineering approach to other aspects of brain function, such as gene expression and to develop new approaches to understanding and treating brain diseases. He serves as serves Scientific Advisory Board Member at Editas Medicine Inc. Dr. Zhang serves as a Member of Scientific Advisory Board at Horizon Discovery Group plc and Horizon Discovery Limited. He successfully engineered the CRISPR-Cas9 system for genome editing in mammalian cells as published online January 3, 2013 in Sciences. He is also one of the 11 core members of the Broad Institute of MIT and Harvard and an Investigator at the McGovern Institute for Brain Research. Since joining MIT and the Broad Institute in January 2011, Dr. Zhang has pioneered the development of genome editing tools for use in eukaryotic cells including human cells from natural microbial CRISPR systems. He has been extremely active in publishing a range of articles on the optimal use and design of the technology. He has published compelling results indicating CRISPR/Cas9-mediated gene editing can be employed in high-throughput genome-wide screens. Dr. Zhang is a Searle Scholar and has received both a Director’s Transformative Research Award and a Directors’ Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics. He is the 2014 recipient of the prestigious NSF Waterman award from the National Science Foundation for his work on the CRISPR-Cas9 system. In 2013 Popular Science named him one of its Brilliant Ten. He was named one of the Top 20 Researchers in 2014 by Nature Biotechnology, which considers the total impact of a scientist's body of published work. Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.
Positions
- Company NameEditas Medicine, Inc.Stock CodeEDITPositionCo-Founder & Scientific Advisory Board Member
